Related Experiment Video
Updated: Jul 18, 2026
12:28
Abbiategrasso Brain Bank Protocol for Collecting, Processing and Characterizing Aging Brains
Published on: June 3, 2020
Corticobasal degeneration -- clinico-pathological considerations
Gabriela Kłodowska-Duda1, Jerzy Słowiński, Grzegorz Opala
1Klinika Neurologii Wieku Podeszłego Slaskiej Akademii Medycznej, ul. Medyków 14, Katowice 40-752, Poland. neurowp@slam.katowice.pl
Folia Neuropathologica
|December 22, 2006
Summary
This report details the first pathologically confirmed case of Corticobasal Degeneration (CBD) in Poland, a rare 4-repeat tauopathy. The case highlights progressive parkinsonism and tau pathology, aiding understanding of this neurodegenerative disease.
Area of Science:
- Neurology
- Neuroscience
- Pathology
Background:
- Corticobasal Degeneration (CBD) is a rare, sporadic 4-repeat tauopathy.
- Understanding the clinical and pathological spectrum of CBD is crucial for diagnosis and treatment.
Observation:
- The first Polish case of pathologically proven CBD is presented.
- The patient exhibited progressive, asymmetric parkinsonism, focal dystonia, aphasia, dysphagia, gaze palsy, and myoclonus.
- Neuroimaging showed asymmetric cortical atrophy, and evoked potentials revealed reduced cortical amplitudes.
Findings:
- Neuropathological examination confirmed cortical atrophy, spongiosis, gliosis, and ballooned neurons.
- Extensive tau-immunoreactivity in neuronal and glial cells was observed, particularly in frontotemporal cortex, basal ganglia, thalamus, and brainstem.
- The findings align with the known pathology of 4-repeat tauopathies.
Implications:
- This case contributes to the pathological characterization of CBD in a new geographic region.
- Further research into sporadic tauopathies like CBD is vital for developing effective symptomatic and curative treatments.
- Improved understanding may accelerate therapeutic advancements for rare neurodegenerative conditions.
More Related Videos
Related Concept Videos
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:24Parkinson Disease ll: Pathophysiology
Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...
01:15Parkinson's Disease: Overview
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...